Cover Image

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review

Xing-Ru Zhang, 1,* Zhi-Yu Jiang, 2,* Zeng-Rui Zhang, 3 Hui-Jun Chen, 1 Ke Wu, 4 Jin-Cai He, 1 Cheng-Long Xie 1 1The Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China; 2The Department of General Surgery, The Sir...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhang XR (Author), Jiang ZY (Author), Zhang ZR (Author), Chen HJ (Author), Wu K (Author), He JC (Author), Xie CL (Author)
Format:	Book
Published:	Dove Medical Press, 2020-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience
by: Szabolcs Szatmári, et al.
Published: (2024)

Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Observations and Dilemmas after 10 Years of Real-Life Experience
by: József Attila Szász, et al.
Published: (2022)

Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Retraction]
by: Hinz M, et al.
Published: (2021)

Xanthonychia Due to Staining From Carbidopa-Levodopa
by: Jonathan Kyle Hwang, et al.
Published: (2023)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018)

Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Expression of Concern]
by: Hinz M, et al.
Published: (2020)

Istradefylline: A novel agent in the treatment of "off" episodes associated with levodopa/carbidopa use in Parkinson disease
by: Lauren Cummins, et al.
Published: (2022)

Large left posterior fossa meningioma presenting with quadriplegia in a woman with history of carbidopa-levodopa resistant parkinsonism
by: Antonio Jose Reyes, et al.
Published: (2019)

The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Retraction]
by: Hinz M, et al.
Published: (2021)

Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC‐HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel
by: John P. Savaryn, et al.
Published: (2024)

The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Expression of Concern]
by: Hinz M, et al.
Published: (2020)

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
by: Emelia Priscilla Imbeah, et al.
Published: (2022)

A case of carbidopa/levodopa associated colitis mimicking inflammatory bowel disease
by: Michael J. Steel, et al.
Published: (2022)

Parkinson's disease: carbidopa, nausea, and dyskinesia
by: Hinz M, et al.
Published: (2014)

Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics
by: Benedicta Obenewaa Dankyi, MPhil, et al.
Published: (2020)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018)

In situ thermosensitive gel of levodopa: Potential formulation for nose to brain delivery in Parkinson disease
by: Shohreh Alipour, et al.
Published: (2020)

Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices
by: Erik Wollmer, et al.
Published: (2017)

Poly(acrylic acid)/Poly(vinyl alcohol) Microarray Patches for Continuous Transdermal Delivery of Levodopa and Carbidopa: In Vitro and In Vivo Studies
by: Yaocun Li, et al.
Published: (2024)

Levodopa versus levodopa sparing in early parkinson's disease: can we meet halfway?
by: Mayela Rodríguez-Violante, et al.
Published: (2024)

The Parkinson's disease death rate: carbidopa and vitamin B6
by: Hinz M, et al.
Published: (2014)

Advances with microRNAs in Parkinson’s disease research
by: Ma L, et al.
Published: (2013)

Levodopa-based device-aided therapies for the treatment of advanced Parkinson's disease: a social return on investment analysis
by: Inez Denham, et al.
Published: (2024)

Levodopa-induced Dyskinesias in Parkinson's Disease: Current Knowledge and Future Scenarios
by: Francesca Morgante
Published: (2015)

Parkinson's disease: general features, effects of levodopa treatment and future directions
by: Marco Aurelio M Freire, et al.
Published: (2010)

Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis
by: Amélie Marsot, et al.
Published: (2017)

Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson's Disease
by: Alfonsina Tirozzi, et al.
Published: (2021)

Gait Analysis of Old Individuals with Mild Parkinsonian Signs and Those Individuals’ Gait Performance Benefits Little from Levodopa
by: Wu Z, et al.
Published: (2021)

Assessing the Neurotoxicity of a Sub-Optimal Dose of Rotenone in Zebrafish (<i>Danio rerio</i>) and the Possible Neuroactive Potential of Valproic Acid, Combination of Levodopa and Carbidopa, and Lactic Acid Bacteria Strains
by: Ovidiu-Dumitru Ilie, et al.
Published: (2022)

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
by: Annus Á, et al.
Published: (2017)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease
by: Sebastiano Gangemi, et al.
Published: (2003)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa-Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats
by: Wen-Wen Wang, et al.
Published: (2019)

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
by: Faddoul L, et al.
Published: (2018)

Co-Application of C16 and Ang-1 Improves the Effects of Levodopa in Parkinson Disease Treatment
by: Fu XX, et al.
Published: (2022)

Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier
by: Kaili Liang, et al.
Published: (2024)

Carbidopa Capsules for Insulinoma Diagnostic: Compounding and Stability Study
by: Curti Christophe, et al.
Published: (2020)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease
by: Marianne Luinstra, et al.
Published: (2019)

Dramatic Improvement in Juvenile Parkinsonism after Levodopa Treatment in a Patient Negative for the PANK2 Mutation
by: Syuan-Yu Hong, et al.
Published: (2016)

A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease
by: Debleena Guin, et al.
Published: (2017)